NHLBI Research and Policy Update
Number 15   March 2005
This electronic distribution list will provide updates from the NHLBI Web Site for the research community. The Updates will be sent as needed, but no more than once a week.


Funding Updates

Please Note: Links to RFAs and PAs will take you to the NIH Web site

RFA-HL-05-010: Pediatric Heart Network

Receipt Dates:	Letter of Intent, August 26, 2005
	Application, September 23, 2005

RFA-HL-05-013: Innovative Technologies for Engineering Small Blood Vessels

Receipt Dates:	Letter of Intent, April 18, 2005
	Application, May 17, 2005

RFA-HL-05-003: Heart Failure Clinical Research Network—Frequently Asked Questions

RFA-HL-04-035: Summer Institute Program to Increase Diversity in Health-Related Research

Receipt Dates:	Letter of Intent, August 14, 2005
	Application, September 14, 2005

PAR-05-063: Collaborations with National Centers for Biomedical Computing
(expires January 18, 2008)

PA-05-058: Lung Response to Inhaled Highly Toxic Chemicals
(expires February 28, 2008)

For additional initiatives, please visit the following Web page:
NHLBI Grants and Contracts page


Policy Updates

Model Organisms for Biomedical Research: NIH/NHLBI Policy on Sharing Organisms and Related Resources

For additional policy documents, please visit Funding / Award Policy section on the following Web page:
Funding, Training, and Policies


Training Updates

NHLBI NRSA T32 Supplemental Guidelines (updated)

Helpful Hints for K24 Applicants (updated)

For more information on training and career development programs, please visit the following Web page:
Training and Career Development


Meetings

List of upcoming meetings

National Heart, Lung, and Blood Advisory Council Meeting, June 16, 2005

For more information, and the most current list of upcoming meetings, please visit the following Web page:
Announcements of NHLBI Meetings, Conferences, and Events

Reports of past meetings

Cerebrovascular Biology and Disease, Working Group Summary, January 28, 2005

NIH Conference on Dietary Supplements, Coagulation, and Antithrombotic Therapies, Executive Summary, January 13-14, 2005

Peripheral Arterial Disease (PAD) Coalition: Inaugural Meeting Summary, June 17, 2004

Healthy Weight Community Outreach Initiative, Strategy Development Workshop Report, February 17-18, 2004

For more information on past meetings, please visit the following Web page:
Workshop and Meeting Summaries, and Other Scientific Reports


Press Releases

Statement from Elizabeth G. Nabel, M.D., Director of the National Heart, Lung, and Blood Institute of the National Institutes of Health on the Findings of the Women's Health Study, March 7, 2005

For additional Press Releases, please visit the following Web page:
Current Press Releases


Selected NHLBI Vacancies

The NHLBI has no vacancies to highlight at this time.

Note: There are often changes and additions, for the most current information, please visit the NHLBI Jobs Opportunities page


Other Items of Interest

NHLBI Fact Book, Fiscal Year 2004

New Datasets Available:
The Beta-Blocker Heart Attack Trial (BHAT)
The Beta-Blocker Heart Attack Trial (BHAT) was a National Heart, Lung, and Blood Institute-sponsored, multicenter, randomized, double-blind, and placebo-controlled trial designed to test whether the regular administration of propranolol hydrochloride to men and women who had experienced at least one myocardial infarction would result in a significant reduction in total mortality during a two- to four-year period.

The Lipid Research Clinics
The Lipid Research Clinics began under the sponsorship of the National Heart, Lung, and Blood Institute, National Institutes of Health. Part of this program was the Lipid Research Clinics Prevalence Study, a standardized series of cross-sectional surveys of various North American populations designed to determine the prevalence of dyslipidemias and to describe the distributions of lipids and lipoproteins in major ethnic and social groups.

The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT),
The LRC-CPPT was a multicenter, randomized, double-blind study, designed to test the efficacy of cholesterol lowering in reducing risk of coronary heart disease (CHD). The LRC-CPPT findings showed that reducing total cholesterol by lowering LDL-C levels can diminish the incidence of CHD morbidity and mortality in men at high risk for CHD because of raised LDL-C levels. This clinical trial provided strong evidence for a causal role for these lipids in the pathogenesis of CHD (JAMA, 251(3), 351-64 (January 20, 1984).

An Archive of the current and past issues is available on the NHLBI Web site.